Histone methyltransferase SMYD1: playing a crucial role in disease progression

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Histone methyltransferase SET and MYND domain-containing 1 (SMYD1), a member of the SMYD family, catalyzes the methylation of lysine residues on histone proteins. This modification is pivotal in regulating chromatin structure and gene expression, influencing processes such as cell proliferation, differentiation, and development. Primarily expressed in muscle tissues, SMYD1 plays a crucial role in muscle development and function. However, accumulating evidence suggests its involvement in the progression of various diseases, including cancer, cardiovascular diseases, and metabolic disorders. By modulating key signaling pathways and gene expression profiles, SMYD1 affects cellular processes such as cell cycle regulation, apoptosis, and inflammation. This review aims to explore the multifaceted roles of SMYD1 in disease progression, highlighting its potential as a therapeutic target. Understanding the molecular mechanisms underlying the effects of SMYD1 will be essential for developing strategies to manipulate its activity for disease prevention and treatment.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.